To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
This study is a Phase 1 Randomized, Double-blind, Three-arm, Parallel Group, Single-dose
Study to compare the PK, safety and immunogenicity of the proposed biosimilar test product
CT-P16 with EU-approved Avastin and US-licensed Avastin after a single IV infusion of 5mg/kg
of each product to healthy male subjects